

Corp. Off.: 502, Kanakia Atrium - 2,
Next to Courtyard Marriott Hotel,
Andheri Kurla Road, Andheri (East),
Mumbai - 400 093 (India)
Ph.: +9122 61933100 Fax : +91 22 61933114

22nd July, 2020



To BSE Limited Department of Corporate Services, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400001	To National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Mumbai – 400050
Scrip Code – 533543	Scrip Symbol - BROOKS

Dear Sir/ Madam,

Sub: Disclosure under Regulation 30 read with Schedule III of SEBI (Listing Obligation and Disclosures Requirements) Regulations, 2015.

This is to inform that, as per Companies (Meetings of Board and its Powers) Amendment Rules, 2020, the meeting of Board of Directors of Brooks Laboratories Limited (“the Company”) has been duly convened on 3rd September, 2020 through video conferencing/audio-visual means; and pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligation and Disclosures Requirements) Regulations, 2015, inter-alia considered and approved the following:

1. The Board has approved the reappointment of Mr. Atul Ranchal as Whole time Director designated as Chairman of the Company for further term of five years commencing from 1st November, 2020 subject to approval of Shareholders in their forthcoming General Meeting.
2. The Board has approved the reappointment of Mr. Rajesh Mahajan as Managing Director of the Company for further term of five years commencing from 1st November, 2020 subject to approval of Shareholders in their forthcoming General Meeting.
3. The Board has approved the new set of Memorandum of Association with respect to the object clause (Clause III) of the Memorandum of Association of the Company and such other amendments as may be required to align the Memorandum of Association with the provisions of the Companies Act, 2013, subject to the approval of Shareholders in their forthcoming General Meeting.
4. The Board has approved the transfer of assets related to the Baddi facility to a Special purpose vehicle to be incorporated as a wholly owned subsidiary of the Company by way of slump sale subject to the approval of Shareholders in their forthcoming General Meeting.



(2)

The meeting of the Board of Directors commenced at 6:00 P.M and concluded at 6:30 P.M.

We request you to kindly take this in your record.

Thanking you,

Yours Sincerely

For **BROOKS LABORATORIES LIMITED**



Jyoti Sancheti

(Company Secretary and Compliance Officer)

